Stay updated on Risankizumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Risankizumab in Atopic Dermatitis Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.3.2 is now displayed, replacing v3.3.1 in the page footer; the change is cosmetic and does not affect the study content or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedPublications section updated to note that publications are automatically filled from PubMed and may not be about the study (Revision: v3.3.1). The previous PubMed listing description was removed and replaced with the new wording (Revision: v3.2.0).SummaryDifference0.1%

- Check27 days agoChange DetectedRemoved the government funding status notice from the page; core study content and key details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedNo substantive changes were observed; the screenshots show only minor layout adjustments with no changes to study content, eligibility criteria, or dates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check70 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference1%

- Check77 days agoChange DetectedThe page has been updated to indicate a new version (v3.1.0) and removes several older MedlinePlus topics (drug safety, counterfeit drugs, pharmaceutical preparations, and substandard drugs) along with the previous revision note (v3.0.2).SummaryDifference0.2%

Stay in the know with updates to Risankizumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in Atopic Dermatitis Clinical Trial page.